GlassScriptPhysician profile
Ivan Alejandro Munoz-Almaraz
NPI 1457834137
$1,720.45
in general payments reported to CMS, 2019-2025
24 companies · $431 in 2025
The $431 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.37 · 2022: $115 · 2023: $528 · 2024: $613 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,572.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $365.94 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Regeneron Healthcare Solutions, INC. | $160.06 | 2023-2025 | Dupixent |
| Novo Nordisk INC | $151.03 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Exact Sciences Corporation | $121.80 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $119.13 | 2023-2024 | |
| Dexcom, INC. | $110.39 | 2022-2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $103.56 | 2023-2025 | Bexsero, Rotarix, Shingrix |
| Cranial Technologies, INC | $70.09 | 2024-2025 | Doc Band |
| Amgen INC. | $64.68 | 2023-2024 | Repatha, Otezla |
| Boston Scientific Corporation | $55.64 | 2022-2023 | Resolution Clip |
| Hologic Sales and Service, LLC | $51.10 | 2021-2024 | Aptima |
| Astrazeneca Pharmaceuticals LP | $42.31 | 2023-2024 | Airsupra, Farxiga |
| Shield Therapeutics INC | $39.58 | 2024 | |
| Gilead Sciences, INC. | $38.58 | 2023 | Epclusa |
| Sumitomo Pharma America, INC. | $36.18 | 2024 | Myfembree |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $31.91 | 2024 | Ycanth |
| Merck Sharp & Dohme LLC | $30.52 | 2025 | Enflonsia, Vaxelis, M-M-R II |
| Abbott Laboratories | $29.00 | 2023 | Freestyle Libre 2 |
| Xeris Pharmaceuticals, INC. | $22.77 | 2025 | Recorlev |
| Sage Therapeutics, LLC | $18.49 | 2024 | |
| Phadia US INC. | $16.15 | 2021 | |
| Pfizer INC. | $14.23 | 2024 | |
| Mannkind Corporation | $13.82 | 2025 | |
| Phathom Pharmaceuticals, INC. | $13.49 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Munoz-Almaraz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.